Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jean Lacau St Guily is active.

Publication


Featured researches published by Jean Lacau St Guily.


Laryngoscope | 2005

Facial Nerve Dysfunction After Parotidectomy: The Role of Local Factors

Christophe Gaillard; Sophie Périé; B. Susini; Jean Lacau St Guily

Objectives/Hypothesis: The objective was to analyze the incidence and factors associated with facial nerve dysfunction after conservative parotidectomy with facial nerve dissection.


Head & Neck Oncology | 2010

Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database

Jean Lacau St Guily; Isabelle Borget; Alexandre Vainchtock; Vanessa Rémy; Claire Takizawa

BackgroundWith 16,005 new cases and 5,406 related deaths in 2005, France is particularly concerned by Head and Neck (H&N) cancers. In addition to tobacco and alcohol, Human Papillomavirus (HPV) has been reported as a risk factor for H&N cancers. The literature on the burden of these cancers in Europe is scarce. This study was performed to assess the medical and economical burden of hospitalisations for H&N cancers in France.MethodsThe French national hospital database (PMSI), in which admissions to public and private hospitals are recorded, was retrospectively analysed to assess the annual number of patients hospitalised for H&N cancers and associated hospital costs from the healthcare payer perspective. ICD-10 codes (16 codes classified as oral cavity, oropharynx, pharynx, salivary glands and larynx) were used to extract admissions for these cancers. Hospital stays, chemotherapy and radiotherapy sessions were extracted to assess patients management. Costs of admissions were obtained from French official tariffs.ResultsIn 2007, there were 36 268 patients hospitalised for H&N cancers, of whom 81% were men, corresponding to 60 200 hospital stays and 287 846 sessions of chemo- or radio-therapy. Oropharynx cancer was the most frequent (28% of patients), followed by oral cavity cancer (25% of patients). The peak of frequency was observed in the 55-59 years age group. Patients were mainly treated in medicine (48%) and surgery (23%) units. Mean annual cost per patient ranged from €2 764 to €7 673 leading to a total hospital cost of €323 millions in 2007 (including hospitalization and expensive drugs). With 26% of H&N cancers attributable to HPV infections, 9 430 patients were hospitalized due to HPV-related H&N cancers, representing €138 million in 2007.ConclusionEven without taking into account the rehabilitation costs, the hospital burden of H&N cancers is considerable.


Journal of Neuropathology and Experimental Neurology | 2013

Atrophy, Fibrosis, and Increased PAX7-Positive Cells in Pharyngeal Muscles of Oculopharyngeal Muscular Dystrophy Patients

Teresa Gidaro; Elisa Negroni; Sophie Périé; Massimiliano Mirabella; Jeanne Lainé; Jean Lacau St Guily; Gillian Butler-Browne; Vincent Mouly; C. Trollet

Oculopharyngeal muscular dystrophy (OPMD) is a late-onset autosomal dominant inherited dystrophy caused by an abnormal trinucleotide repeat expansion in the poly(A)-binding-protein-nuclear 1 (PABPN1) gene. Primary muscular targets of OPMD are the eyelid elevator and pharyngeal muscles, including the cricopharyngeal muscle (CPM), the progressive involution of which leads to ptosis and dysphagia, respectively. To understand the consequences of PABPN1 polyalanine expansion in OPMD, we studied muscle biopsies from 14 OPMD patients, 3 inclusion body myositis patients, and 9 healthy controls. In OPMD patient CPM (n = 6), there were typical dystrophic features with extensive endomysial fibrosis and marked atrophy of myosin heavy-chain IIa fibers. There were more PAX7-positive cells in all CPM versus other muscles (n = 5, control; n = 3, inclusion body myositis), and they were more numerous in OPMD CPM versus control normal CPM without any sign of muscle regeneration. Intranuclear inclusions were present in all OPMD muscles but unaffected OPMD patient muscles (i.e. sternocleidomastoid, quadriceps, or deltoid; n = 14) did not show evidence of fibrosis, atrophy, or increased PAX7-positive cell numbers. These results suggest that the specific involvement of CPM in OPMD might be caused by failure of the regenerative response with dysfunction of PAX7-positive cells and exacerbated fibrosis that does not correlate with the presence of PABPN1 inclusions.


Laryngoscope | 2000

Conservative Surgery in T3–T4 Pharyngolaryngeal Squamous Cell Carcinoma: An Alternative to Radiation Therapy and to Total Laryngectomy for Good Responders to Induction Chemotherapy

Jean‐Baptiste Lecanu; Guy Monceaux; Sophie Périé; B. Angelard; Jean Lacau St Guily

Objective To evaluate the possibility of preservation of the larynx after neoadjuvant chemotherapy by performing a conservative surgery instead of total laryngectomy initially planned, in patients with previously untreated laryngeal and piriform sinus squamous cell carcinoma (SCC).


Oral Oncology | 2014

A predictive transcriptomic signature of oropharyngeal cancer according to HPV16 status exclusively.

Haitham Mirghani; Nicolas Ugolin; Catherine Ory; Marine Lefevre; Sylvain Baulande; Paul Hofman; Jean Lacau St Guily; Sylvie Chevillard; Roger Lacave

OBJECTIVEnHuman-papillomaviruses (HPV) type 16 is a causative agent in an increasing subset of oropharyngeal squamous cell carcinomas (OPSCCs). These tumors have distinct oncogenic mechanisms and a more favorable prognosis than tobacco-induced OPSCCs. Although these differences emphasize the need for a specific therapeutic approach, HPV status is still not used to guide treatment. A better characterization of the molecular profile related to HPV16-induced OPSCC might help to develop personalized treatments.nnnPATIENTS AND METHODSnUsing a human whole-genome DNA-microarray, we have examined the gene expression profiles in 15 HPV-negative and 15 transcriptionally-active HPV-positive OPSCCs. The study was conducted in two steps. Firstly, a learning/training-set consisting of 8 HPV16-positive and 8 HPV16-negative OPSCCs was analyzed to identify a specific signature. Potentially confounding factors (stage, sex and tobacco) were equally distributed in both groups. Subsequently the robustness of this signature was confirmed by blind case-by-case classification of a validation-set composed of the 14 remaining tumors.nnnRESULTSnWe have identified a signature composed of 224 genes, which discriminates HPV16-induced OPSCC from their HPV-negative counterparts. After the blind classification of the 14 tumours, the viral status was revealed: 13 out of 14 tumors were correctly classified according to tumor etiology, 1/14 was not determined and none were misclassified. Several of the differentially expressed genes were involved in cell-cycle regulation, DNA replication and repair, transcription regulation, immune response and apoptosis.nnnCONCLUSIONnOur study contributes to a better understanding of pathogenic mechanisms involved in the development of HPV-positive OPSCCs and in the identification of potential therapeutic targets.


Bulletin Du Cancer | 2014

Épidémiologie et anatomie des cancers ORL

Sophie Périé; Marie Meyers; Olivia Mazzaschi; Olivier De Crouy Chanel; Bertrand Baujat; Jean Lacau St Guily

Oral cavity and pharyngeal cancers account for 75% of head and neck cancers and are the fourth most spread cancer in men. Their incidence has decreased since 1980 in men (incidence from 2011 gives 13,930 for lip, oral cavity, pharyngeal and laryngeal carcinomas) but has increased in women, linked to the more recent smoking or alcohol intoxication in women. In addition to the smoking or alcohol consumption risk factors, the EBV role in nasopharyngeal carcinomas, HPV in the oropharyngeal carcinomas and professional exposures in paranasal sinuses cancers are recognized. Head and neck cancers are the fifth most common cancer in men mortality in France. Extended anatomical sites reflect the diagnostics complexity specific to some locations (sinuses, nasopharynx), possible therapies and prognosis depending on the affected site.


Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2013

Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen.

L. Monnier; Emmanuel Touboul; C. Durdux; Philippe Lang; Jean Lacau St Guily; Florence Huguet

Standard treatment for unresectable advanced head and neck squamous cell carcinoma is chemoradiotherapy, which can be toxic, particularly among patients with coexisting medical conditions. We report our experience with the hypofractionated radiotherapy regimen Irradiation HypoFractionnée 2 Séances Quotidiennes (IHF2SQ).


Infectious Agents and Cancer | 2017

Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe

Susanne Hartwig; Jean Lacau St Guily; Géraldine Dominiak-Felden; Laia Alemany; Silvia de Sanjosé

BackgroundIn addition to cervical cancer, human papillomavirus (HPV) is responsible for a significant proportion of cancers and precancerous lesions of the vulva, vagina, anus, penis, head and neck, as well as genital warts. We estimated the annual number of new cases of these diseases attributable to 9-valent HPV vaccine types in women and men in Europe.MethodsThe annual number of new cancers of the cervix, vulva, vagina, anus, penis, and selected head and neck sites in the population of the European Medicines Agency territory was estimated based on age-specific incidence rates extracted from Cancer Incidence in 5 Continents, Volume X and Eurostat population data for 2015. The annual number of new cancers attributable to 9-valent HPV vaccine types was estimated by applying the HPV attributable fraction from reference publications based on a large European multicenter study. For non-cervical cancers, HPV attributable fractions were based on oncogenically-active HPV infections only (i.e., detection of HPV DNA and either mRNA and/or p16 positivity). For precancerous lesions of the cervix, vulva, vagina, and anus, and for genital warts, previously published estimations were updated for the 2015 population.ResultsThe annual number of new cancers attributable to 9-valent HPV vaccine types was estimated at 47,992 (95% bound: 39,785-58,511). Cervical cancer showed the highest burden (31,130 cases), followed by head and neck cancer (6,786 cases), anal cancer (6,137 cases), vulvar cancer (1,466 cases), vaginal cancer (1,360 cases), and penile cancer (1,113 cases). About 81% were estimated to occur in women and 19% in men. The annual number of new precancerous lesions (CIN2+, VIN2/3, VaIN2/3, and AIN2/3) and genital warts attributable to 9-valent HPV vaccine types was estimated at 232,103 to 442,347 and 680,344 to 844,391, respectively.ConclusionsThe burden of cancers associated with 9-valent HPV vaccine types in Europe is substantial in both sexes. Head and neck cancers constitute a heavy burden, particularly in men. Overall, about 90% of HPV-related cancers, 80% of precancerous lesions, and 90% of genital warts are expected to be attributable to 9-valent HPV vaccine types each year, demonstrating the important preventive potential of the 9-valent HPV vaccine in Europe.


International Journal of Cancer | 2015

Deep brush‐based cytology in tonsils resected for benign diseases

Silvia Franceschi; Jean-Damien Combes; Véronique Dalstein; Stéphanie Caudroy; Gary M. Clifford; Tarik Gheit; Massimo Tommasino; Christine Clavel; Jean Lacau St Guily; Philippe Birembaut

A fraction of oropharyngeal cancer (OPC), especially in the tonsil, is caused by human papillomavirus (HPV), mainly HPV16. Noninvasive diagnostic methods to detect precancerous lesions in the tonsil would be useful, e.g., liquid‐based cytology (LBC). However, ill‐characterized precancerous lesions may be hidden in the depth of the tonsillar crypts. We therefore conducted a study on HPV and tonsillar precancerous lesions to evaluate, among other things, the utility of LBC obtained by deep brushing of the resected tonsils. Two hundred non‐paediatric patients (mean age: 30.3 years) who underwent tonsillectomy for infection‐related conditions (69%) or other conditions (mainly obstructive sleep apnoea, 31%) were included. An ultra‐sensitive Luminex bead‐based platform was used to test for the DNA of 21 mucosal HPV types; 56% of slides were unsatisfactory due to low number of squamous epithelial cells or the masking effect of a large number of lymphocytes. Three patients (1.5%; 95% CI: 0.5–4.3) showed suspicious cytological findings (atypical squamous cells‐cannot exclude high‐grade squamous intraepithelial lesion, ASC‐H) while 3 others were HPV‐positive (2 for HPV16 and 1 for HPV39). None of the ASC‐H patients and HPV‐positive patients showed dysplasia at histological examination. The rarity of HPV infection in the tonsil conflicts with the relatively frequent detection of the virus in the mouth. In conclusion, aggressive deep brushing of tonsils, while hardly applicable in vivo, is unlikely to be a reliable method to detect precancerous lesions. The absence of OPC screening modalities places the priority on multi‐purpose primary prevention strategies, i.e., HPV vaccination and reduction of smoking and drinking.


Otolaryngology-Head and Neck Surgery | 2008

Clinical significance of micrometastases detection in lymph nodes from head and neck squamous cell carcinoma

Yanan Xu; Marine Lefevre; Sophie Périé; Lei Tao; Patrice Callard; Jean-François Bernaudin; Jean Lacau St Guily

OBJECTIVE: Study the clinical relevance of micrometastases in head and neck squamous cell carcinoma (HNSCC). METHODS: We reviewed the outcome of 31 patients who underwent neck dissection for HNSCC with lymph node analysis by cytokeratin 19 real-time Taqman polymerase chain reaction (CK19RT-PCR) for detection of micrometastasis. Fifteen patients were N+ on histopathology (group 1) and 16 were N-; nine of these 16 patients were CK19RT-PCR positive (group 2), whereas seven were negative (group 3). Local and neck recurrences, metastases, and other tumour sites were recorded during follow-up. RESULTS: Five patients in group 1, eight patients in group 2, and one patient in group 3 experienced a tumor-related event. N-patients in groups 2 and 3 had a different outcome (P < 0.01). CONCLUSION: It is suggested that CK19RTPCR detection of micrometastasis in lymph nodes could be of significant prognostic value in HNSCC, because more aggressive treatment could be indicated in these patients.

Collaboration


Dive into the Jean Lacau St Guily's collaboration.

Top Co-Authors

Avatar

Gary M. Clifford

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Jean-Damien Combes

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Massimo Tommasino

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Silvia Franceschi

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Tarik Gheit

International Agency for Research on Cancer

View shared research outputs
Top Co-Authors

Avatar

Paul Hofman

University of Auckland

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christine Clavel

University of Reims Champagne-Ardenne

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge